0001140361-22-040018.txt : 20221104 0001140361-22-040018.hdr.sgml : 20221104 20221104163958 ACCESSION NUMBER: 0001140361-22-040018 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221104 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221104 DATE AS OF CHANGE: 20221104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ocuphire Pharma, Inc. CENTRAL INDEX KEY: 0001228627 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113516358 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34079 FILM NUMBER: 221362823 BUSINESS ADDRESS: STREET 1: 37000 GRAND RIVER AVE. STREET 2: SUITE 120 CITY: FARMINGTON HILLS STATE: MI ZIP: 48335 BUSINESS PHONE: 248-681-9815 MAIL ADDRESS: STREET 1: 37000 GRAND RIVER AVE. STREET 2: SUITE 120 CITY: FARMINGTON HILLS STATE: MI ZIP: 48335 FORMER COMPANY: FORMER CONFORMED NAME: REXAHN PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20050516 FORMER COMPANY: FORMER CONFORMED NAME: CORPORATE ROAD SHOW DOT COM INC DATE OF NAME CHANGE: 20030423 8-K 1 brhc10043741_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 4, 2022

Ocuphire Pharma, Inc.
(Exact name of registrant as specified in its charter)

Delaware
  
001-34079
  
11-3516358
(State or other jurisdiction
of incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)

37000 Grand River Avenue, Suite 120 Farmington Hills, MI 48335
(Address of principal executive offices and zip code)

248-681-9815
(Registrant’s telephone number including area code)

(Registrant’s former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
  
OCUP
  
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition.

On November 4, 2022, Ocuphire Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
  
  Description
 
Press Release, dated November 4, 2022
104
  
Cover Page Interactive Data File (embedded with Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
OCUPHIRE PHARMA, INC.
Dated: November 4, 2022
    
 
By:
/s/ Mina Sooch
   
Mina Sooch
   
Chief Executive Officer


EX-99.1 2 brhc10043741_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1
 
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update
 
NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022
 
Topline Data from ZETA-1 Phase 2b Trial of Oral APX3330 Expected in Early 2023
 
FARMINGTON HILLS, Mich., November 4, 2022 – Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, announces financial results for the third quarter ended September 30, 2022 and provides a corporate update.
 
“During the third quarter, Ocuphire continued to execute elements of our strategic plan to bring innovative treatments to patients with highly prevalent refractive and diabetic retinal diseases,” said Mina Sooch, MBA, founder and CEO of Ocuphire Pharma. “With enrollment and 24-week treatment completed in over 100 patients in our ZETA-1 Phase 2b trial of APX3330, we look forward to sharing topline results in early 2023, bringing us closer to delivering a potential oral option for diabetic retinopathy patients. We are on track for NDA submission for Nyxol for reversal of mydriasis in the fourth quarter 2022. We have strong momentum and are poised to deliver on multiple catalysts going forward that we believe will create significant value for our company and shareholders.”
 
Key Anticipated Future Milestones
 

 ●
Reversal of Mydriasis (RM): Plan to submit New Drug Application (NDA) with the FDA for Nyxol in RM indication in Q4 2022, with potential approval and commercial launch as first dilation reversal drop in 2023.
 

 ●
Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME): Plan to report top-line results from the ZETA-1 Phase 2b trial of APX3330 in early 2023. APX3330 is a novel oral therapy with a dual mechanism of action in validated pathways, decreasing both abnormal angiogenesis and inflammation. 
 

 ●
Presbyopia: Plan to initiate VEGA-2 Phase 3 trial in Q4 2022 investigating Nyxol alone and Nyxol with 0.4% low-dose pilocarpine (LDP) as adjunctive therapy. In addition, VEGA-3 (2nd Phase 3) and LYRA-1 (1-year safety) trials are planned to begin in 2023.
 
Third Quarter and Recent Business Highlights
 
Clinical and Regulatory Development
 

 ●
In September, the Company announced that the last of the 103 enrolled patients in the ZETA-1 Phase 2b trial of oral APX3330 for the treatment of diabetic retinopathy (DR) completed the final visit of the 24-week study.
 

 ●
In September, the Company announced that U.S. Food and Drug Administration (FDA) has granted a small-business waiver of the Prescription Drug User Fee Act (PDUFA) fee of $3.1 million for the 505(b)(2) NDA for Nyxol.
 
Presentations, Publications, and Conferences
 

 ●
Year to date, Ocuphire was represented at multiple key ophthalmological conferences with updates on Nyxol in RM, presbyopia and night vision disturbances, as well as masked safety data for APX3330 in DR. In total, more than 25 papers, posters, and panel talks were presented over 20 medical and industry conferences. Highlights in October and early November 2022:
 

 ●
Mitchell Jackson, MD presented a poster highlighting presbyopia data at the American Academy of Ophthalmology Annual Meeting in Chicago, IL.
 

 ●
Prominent optometry thought leaders and clinical trial investigators Justin Schweitzer, OD, Mitch Ibach, OD, Leslie O’Dell, OD, Shane Foster, OD, Doug , Devries, OD and Shane Kannarr, OD presented six posters on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting in San Diego, CA.
 

 ●
The Company announced publication of an earlier Phase 2 clinical trial in patients with severe night vision disturbances in the BMC Ophthalmology peer-reviewed journal. The publication can be accessed here.


●
In October, the Company held a Key Opinion Leader (KOL) webinar on oral APX3330. The event featured presentations by KOLs Peter Kaiser, MD, from the Cleveland Clinic, Caroline Baumal, MD, from Tufts Medical Center, and David Lally, MD, from New England Retina Consultants. KOL. The discussion highlighted the unmet need and current treatment landscape for DR/DME and included new data on study demographics and 24-week masked safety data from the ZETA-1 trial. A replay of the event can be found on the company’s corporate website here.

Corporate
 

 ●
On August 2, 2022, Ocuphire was granted extended intellectual property protection for Nyxol with the issuance of U.S. Patent No. 11,400,077 with claims directed to methods for mydriasis treatment using phentolamine, extended by 5 years into 2039.


●
In September, the Company appointed seven new Key Opinion Leaders (KOLs) across retina, cornea/refractive, and medical optometry to its Medical Advisory Board (MAB): Anat Loewenstein, MD, PhD, Caroline Baumal, MD, Zaina Al-Mohtaseb, MD, Inder Paul Singh, MD, Leslie O’Dell, OD, Selina McGee, OD, Justin Schweitzer, OD.
 
Third Quarter Ended September 30, 2022, Financial Highlights
 
As of September 30, 2022, Ocuphire had cash and cash equivalents of approximately $13.9 million. Based on current projections, management believes the current cash on hand will be sufficient to fund operations into the fourth quarter of 2023. Net cash used in operating activities in the third quarter of 2022 was $4.5 million, with a cumulative total for the nine months ended September 30, 2022, of $14.5 million.
 
General and administrative expenses for the three and nine months ended September 30, 2022, were $1.7 million and $5.2 million, respectively, compared to $1.6 million and $6.7 million, respectively, for the three and nine months ended September 30, 2021. The increase from the comparable quarter in 2021 was largely attributed to an increase in legal costs on a net basis. The decrease from the comparable nine months in 2021 was largely attributed to a non-cash settlement with certain investors in the comparable prior year period, offset by a slight increase in general and administrative expenses attributed to higher payroll and other operating costs in the current year period when compared to the comparable prior year period.
 
Research and development expenses for the three and nine months ended September 30, 2022, were $2.8 million and $10.8 million, respectively, compared to $3.1 million and $10.4 million, respectively, for the three and nine months ended September 30, 2021. The decrease from the comparable quarter in 2021 was primarily attributable to the completion of clinical trials and the timing of manufacturing activities for Nyxol and APX3330. The increase from the comparable nine months in 2021 was primarily attributable to the timing of clinical trials and manufacturing activities for Nyxol and APX3330 as well as regulatory, preclinical and other development activities.
 
The total loss from operations for the three and nine months ended September 30, 2022, was $4.5 million and $16.0 million, respectively, compared to $4.2 million and $16.6 million, respectively, for the three and nine months ended September 30, 2021.
 
Net loss for the three and nine months ended September 30, 2022, was $4.5 million and $16.1 million, respectively, compared to $4.2 million and $50.4 million, respectively, for the three and nine months ended September 30, 2021. Net loss per share for the three and nine months ended September 30, 2022, was ($0.22) and ($0.82) per share, respectively, compared to ($0.25) and ($3.64) per share, respectively, for the comparable periods in 2021.
 
For further details on Ocuphire’s financial results, refer to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, to be filed with the Securities and Exchange Commission.
 
About Ocuphire Pharma
 
Ocuphire is a publicly traded (Nasdaq: OCUP), clinical-stage, ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of refractive and retinal eye disorders.
 
The Company’s lead product candidate, Nyxol® eye drops (0.75% phentolamine ophthalmic solution), is a once-daily, preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size and is being developed for three indications, including reversal of pharmacologically induced mydriasis (RM), presbyopia and dim light or night vision disturbances (NVD). Nyxol has been studied in 12 completed clinical trials, including recently reported positive data from the following trials:
 

 ●
MIRA-2 (NCT04620213), MIRA-3 (NCT05134974), and MIRA-4 (NCT05223478 pediatric safety trial) registration trials for the treatment of RM
 

 ●
VEGA-1 (NCT04675151) Phase 2 trial of Nyxol for treatment of presbyopia, which evaluated both Nyxol as a single agent and Nyxol with low dose pilocarpine (“LDP”) 0.4% as adjunctive therapy
 

 ●
LYNX-1 (NCT04638660) Phase 3 trial of Nyxol for night vision disturbances (NVD)
 
Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). APX3330 has been studied in 11 Phase 1 and 2 trials. The Company announced the completion of last patient last visit in late August in ZETA-1 (NCT04692688).
 
For more information, visit www.ocuphire.com. 
 
Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning clinical and regulatory milestones for Ocuphire’s indications, including Ocuphire’s potential NDA submission, initiation of certain trials, and receipt of topline data, Ocuphire’s business strategy and potential growth, and commercialization of Ocuphire’s product candidates. These forward-looking statements are based upon Ocuphire’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (I) the success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) the effects of COVID-19 on clinical programs and business operations, (ix) the success and timing of commercialization of any of Ocuphire’s product candidates and (x) the maintenance of Ocuphire’s intellectual property rights. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
 
Contacts
 
Corporate
Investor Relations
Mina Sooch, MBA
CEO & Founder
ir@ocuphire.com
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
Bret Shapiro
CoreIR
brets@coreir.com

Ocuphire Pharma, Inc.
Condensed Balance Sheets
(in thousands, except share amounts and par value)
 
   
As of
  
   
September 30,
    
December 31,
  
   
2022
    
2021
  
   
(unaudited)
        
Assets
            
Current assets:
            
Cash and cash equivalents
  
$
13,855
    
$
24,534
  
Prepaids and other current assets
    
605
      
1,314
  
Short-term investments
    
101
      
219
  
Total current assets
    
14,561
      
26,067
  
Property and equipment, net
    
7
      
10
  
Total assets
  
$
14,568
    
$
26,077
  
                 
Liabilities and stockholders’ equity
                
Current liabilities:
                
Accounts payable
  
$
1,468
    
$
1,584
  
Accrued expenses
    
1,223
      
1,733
  
Short-term loan
    
—
      
538
  
Total current liabilities
    
2,691
      
3,855
  
Warrant liabilities
    
—
      
—
  
Total liabilities
    
2,691
      
3,855
  
                 
Commitments and contingencies
                
                 
Stockholders’ equity:
                
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of September 30, 2022, and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021.
    
—
      
—
  
Common stock, par value $0.0001; 75,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 20,801,506 and 18,845,828 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively.
    
2
      
2
  
Additional paid-in-capital
    
117,296
      
111,588
  
Accumulated deficit
    
(105,421
)
    
(89,368
)
Total stockholders’ equity
    
11,877
      
22,222
  
Total liabilities and stockholders’ equity
  
$
14,568
    
$
26,077
  

Ocuphire Pharma, Inc.
Condensed Consolidated Statements of Comprehensive Loss
(in thousands, except share and per share amounts)
(Unaudited)

   
For the Three Months Ended
    
For the Nine Months Ended
  
   
September 30,
   
September 30,
 
   
2022
    
2021
    
2022
    
2021
  
Collaborations revenue
  
$
—
    
$
489
    
$
—
    
$
589
  
                                 
Operating expenses:
                                
General and administrative
    
1,703
      
1,595
      
5,215
      
6,707
  
Research and development
    
2,835
      
3,126
      
10,769
      
10,437
  
Total operating expenses
    
4,538
      
4,721
      
15,984
      
17,144
  
Loss from operations
    
(4,538
)
    
(4,232
)
    
(15,984
)
    
(16,555
)
Interest expense
    
—
      
—
      
(9
)
    
—
  
Fair value change of warrant liabilities
    
—
      
—
      
—
      
(33,829
)
Other income (expense), net
    
7
      
2
      
(60
)
    
4
  
Loss before income taxes
    
(4,531
)
    
(4,230
)
    
(16,053
)
    
(50,380
)
Benefit (provision) for income taxes
    
—
      
—
      
—
      
—
  
Net loss
    
(4,531
)
    
(4,230
)
    
(16,053
)
    
(50,380
)
Other comprehensive loss, net of tax
    
—
      
—
      
—
      
—
  
Comprehensive loss
  
$
(4,531
)
  
$
(4,230
)
  
$
(16,053
)
  
$
(50,380
)
Net loss per share:
                                
Basic and diluted
  
$
(0.22
)
  
$
(0.25
)
  
$
(0.82
)
  
$
(3.64
)
Number of shares used in per share calculations:
                                
Basic and diluted
    
20,498,229
      
16,925,006
      
19,635,651
      
13,841,067
  

 


 EX-101.SCH 3 ocup-20221104.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ocup-20221104_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 ocup-20221104_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image01.jpg begin 644 image01.jpg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htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 04, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 04, 2022
Entity File Number 001-34079
Entity Registrant Name Ocuphire Pharma, Inc.
Entity Central Index Key 0001228627
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 11-3516358
Entity Address, Address Line One 37000 Grand River Avenue, Suite 120
Entity Address, City or Town Farmington Hills
Entity Address, State or Province MI
Entity Address, Postal Zip Code 48335
City Area Code 248
Local Phone Number 681-9815
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol OCUP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 8 brhc10043741_8k_htm.xml IDEA: XBRL DOCUMENT 0001228627 2022-11-04 2022-11-04 false 0001228627 8-K 2022-11-04 Ocuphire Pharma, Inc. DE 001-34079 11-3516358 37000 Grand River Avenue, Suite 120 Farmington Hills MI 48335 248 681-9815 false false false false Common Stock, par value $0.0001 per share OCUP NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://ocuphire.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10043741_8k.htm brhc10043741_ex99-1.htm ocup-20221104.xsd ocup-20221104_lab.xml ocup-20221104_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10043741_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10043741_8k.htm" ] }, "labelLink": { "local": [ "ocup-20221104_lab.xml" ] }, "presentationLink": { "local": [ "ocup-20221104_pre.xml" ] }, "schema": { "local": [ "ocup-20221104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ocup", "nsuri": "http://ocuphire.com/20221104", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10043741_8k.htm", "contextRef": "c20221104to20221104", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://ocuphire.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10043741_8k.htm", "contextRef": "c20221104to20221104", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ocuphire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001140361-22-040018-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-040018-xbrl.zip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end